Testimony Before the FDA’s Vaccines and Related Biological Products Advisory Committee Regarding Booster (Third) Doses of the Pfizer-BioNTech COVID-19 Vaccine
In testimony before a meeting of the Food and Drug Administration’s (FDA’s) Vaccines and Related Biological Products Advisory Committee, Public Citizen argued that Pfizer and BioNTech have failed to provide sufficient data to assess the risk-benefit profile of a booster (third) dose of their COVID-19 vaccine in individuals aged 16 or older in the general population.
See Public Citizen’s other work on the COVID-19 pandemic.